All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by AbbVie, Johnson & Johnson, Roche and sobi, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
Lenalidomide approved by the FDA for follicular and marginal zone lymphoma
The US Food and Drug Administration has approved lenalidomide in combination with a rituximab product for previously treated follicular lymphoma (FL) and previously treated marginal zone lymphoma (MZL).
Two clinical trials contributed to the approval, AUGMENT (NCT 01938001), and MAGNIFY (NCT 01996865). In MAGNIFY, the single-arm component consisted of 232 patients with relapsed or refractory FL, MZL or mantle cell lymphoma. Patients received 12 induction cycles of lenalidomide and rituximab. The objective response rate (ORR) was 59% (104/177; 95% CI, 51%, 66%) for patients with FL, and 51% (23/45; 95% CI, 36%, 66%) for patients with MZL.
Median response duration was not reached, with a median follow-up of 7.9 months in patient with FL, and 11.5 months in patients with MZL.
In AUGMENT, 358 patients with relapsed or refractory (R/R) FL or MZL randomly received either lenalidomide and rituximab, or rituximab and a placebo. The primary endpoint of the study was progression-free survival (PFS), determined by an independent review committee. Median PFS in the lenalidomide arm was 39.4 months and 14.1 months in the placebo arm (HR 0.46; 95% CI, 0.34, 0.62; P<0.0001).
The ORR for patients with FL was 80% (118/147; 95% CI, 73%, 86%) in the lenalidomide cohort, compared with 55.4% (82/148; 95% CI, 47%, 64%) in the control group. The ORR for patients with MZL was 65% (20/31; 95% CI, 45%, 81%), in comparison to the control arm at 44% (14/32; 95% CI, 26%, 62%).
Adverse reactions affecting at least 20% of patients in both studies were neutropenia, fatigue, diarrhea, constipation, nausea and cough.
The recommended dose of lenalidomide for FL or MZL is 20 mg orally once daily on days 1—21 of repeated 28-day cycles (up to 12 cycles). Full prescribing information can be found here, and includes a warning alerting health care professionals about the risk of embryo-fetal toxicity, hematologic toxicity, and venous and arterial thromboembolism, which could be life threatening or fatal.
References
Your opinion matters
Which of the following do you consider a key challenge when implementing the BrECADD regimen for the treatment of Hodgkin lymphoma?